TOP2A has been established as a therapeutic target in various malignancies, and its increased expression in T1 compared to T2 and T3 may suggest its role in promoting tumour cell proliferation through the inhibition of p53 pathways [39, 40, 41, 42]. This evidence concerns the gene TP53 and neoplasm.